- Robert Bazemore - President and Chief Executive Officer
- Matthew Ros - Chief Strategy & Business Officer
- Dr. Shefali Agarwal - Chief Medical Officer
- John Weidenbruch - General Counsel
- Andrea Edwards - Head of Human Resources and Organizational Development
- Pamela Strode - Senior Vice President, Regulatory Affairs & Quality Assurance
- Richard Chesworth - Senior Vice President of Research
President and Chief Executive Officer
Robert (Rob) Bazemore has served as President and Chief Executive Officer since September 2015. Prior to joining Epizyme, Rob served as Chief Operating Officer of Synageva, where he established the company's global commercial and medical organization to support the first product launch, and helped lead the broader transition to a sustainable commercial enterprise, through its acquisition in July 2015. With more than 25 years of experience across the life sciences industry, Rob held several senior leadership positions at Johnson & Johnson. This included his role as President of Janssen Biotech, where he led the successful launches of numerous products and indications, including the U.S. launches of the oncology therapies ZYTIGA® and IMBRUVICA®, as well as guiding the company’s worldwide immunology portfolio strategy. Prior to Johnson & Johnson, he worked at Merck & Co., Inc. for 11 years in roles of increasing responsibility, including the launch of SINGULAIR® in the U.S.
Rob received a B.S. in Biochemistry from the University of Georgia. He currently sits on the Board of Directors of Ardelyx, Inc.
Chief Strategy & Business Officer
Matthew (Matt) Ros now serves as Chief Strategy & Business Officer, overseeing Epizyme’s corporate strategy and business functions. He joined Epizyme in May 2016 as the company’s Chief Operating Officer. Before joining Epizyme, Matt served as COO and global head of Sanofi-Genzyme’s $1.4 billion Oncology franchise, leading its restructuring and revised business strategy. Prior to his tenure at Sanofi, Matt served as senior vice president at ARIAD Pharmaceuticals, leading their oncology commercialization efforts. Matt also held positions of increasing responsibility throughout a highly distinguished 17-year career in Bristol-Myers Squibb’s Oncology franchise and contributed to the successful launches of brands that changed the standard of oncology care, including: TAXOL, ERBITUX®, SPRYCEL® and IXEMPRA®. Throughout his nearly three decades in industry, Matt has built a career and reputation on his ability to build and lead organizations to deliver patient-focused results.
Matt earned a BS in Business Administration from SUNY Plattsburgh. Outside of work, Matt can be found enjoying time with his family, improving his golf game or patiently waiting for the Foo Fighters to announce their next concert tour date.
Dr. Shefali Agarwal
Chief Medical Officer
Dr. Shefali Agarwal is Epizyme’s Chief Medical Officer. Prior to joining the company in 2018, Shefali held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Shefali also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA® (niraparib) in ovarian cancer. Shefali has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer. In addition to receiving her medical degree, Shefali holds a master’s of public health and a master’s of science in business.
John Weidenbruch is Epizyme’s General Counsel. With three decades of legal affairs and policy experience, John has served as General Counsel for some of the world’s leading pharmaceutical and biotech organizations, including Biogen, Inc., Idenix Pharmaceuticals, Abraxis BioScience, Amgen and, most recently, Visterra, Inc. John began his career in healthcare policy as a lobbyist for the Consumer Healthcare Products Association (CHPA), formerly known as the Non-Prescription Drug Manufacturer Association.
John graduated with a BS in Sociology from Loyola University in Maryland and earned a JD from Georgetown University Law Center. An alumnus of the board of the trustees, John served as a board member of the American Kidney Fund for seven years.
Head of Human Resources and Organizational Development
Andrea Edwards is Epizyme’s Head of Human Resources and Organization Development. Prior to joining Epizyme, Andrea led her own management consulting and executive coaching firm for companies from local start-ups to large-scale global organizations across diverse industries, including several pharmaceutical and biotechnology clients. Andrea formerly served as Vice President of Performance Management at Fidelity Investments, where she led a cross-enterprise team in the redesign of Fidelity's performance management processes. Andrea brings expertise in global business operations at IBM and The Boston Consulting Group, through her more than 25 years of experience in human resources and evolving leadership and team capabilities.
Andrea earned a BA in English Literature from Boston University and a graduate certification in Executive Coaching from William James College. In her free time, Andrea is the founder of SwiftRiver Horizons, an organization that helps support women managing chronic stress, encouraging them to implement positive changes within their lives and communities.
Senior Vice President, Regulatory Affairs & Quality Assurance
Pamela (Pam) Strode is Epizyme’s Senior Vice President of Regulatory Affairs and Quality Assurance, where she oversees activities related to global regulatory strategy and compliance with GMP, GLP and GCP requirements and standards. Prior to joining Epizyme, Pam served as Vice President of Regulatory Affairs at Cerulean Pharma Inc., where she established the regulatory affairs function. With a regulatory career that spans three decades, Pam has led and supported US and global product development and life cycle management at Boehringer Ingelheim and Bristol-Myers Squibb, including oncology, immunology, virology and infectious disease development. During her tenure at BI, Pam led the global registration strategy for VIRAMUNE®, bringing this important first-in-class non-nucleoside reverse transcriptase inhibitor (NNRTI) to patients during the height of the AIDS pandemic.
Pam graduated from Rutgers University with a BS in Microbiology, and from Temple University with an MS in Quality Assurance and Regulatory Affairs. Beyond her passion for contributing to the sciences in a meaningful way, Pam finds inspiration in the mountains of Vermont, where she can be found on the ski slopes or around the campfire, enjoying time with family and friends.
Senior Vice President of Research
Richard Chesworth, DPhil, serves as Epizyme’s Head of Research. He responsible for pipeline activities from target selection to IND as well as nonclinical support of clinical candidates. Throughout his more than two decades in the pharmaceutical and biotechnology industry, Richard has contributed to the research and development programs of nine clinical drug candidates. Richard joined Epizyme in 2010 from EnVivo Pharmaceuticals where he was head of chemistry. Prior to Envivo Richard held positions at SurfaceLogix and Pfizer.
Richard graduated from Imperial College of Science, Technology and Medicine at the University of London with a BSc in Chemistry, and earned a Doctor of Philosophy in Chemistry at the University of Oxford.